Mantle Cell Lymphoma Clinical Trials

The following clinical trials are currently open and accruing for patients with mantle cell lymphoma.

Contact us at 617-582-8713, kalin_goldstone@dfci.harvard.edu to discuss a patient.

TRIALS FOR RELAPSED/REFRACTORY PATIENTS

<table>
<thead>
<tr>
<th>Trial</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-021</td>
<td>A phase 1/2 study of oral LOXO-305 in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or non-Hodgkin lymphoma (NHL); for patients who have had prior BTK inhibitor with either progression or discontinuation for adverse event</td>
</tr>
</tbody>
</table>

See the following pages for more information about these trials.

These trials are offered through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.
TRIALS FOR PATIENTS WITH RELAPSED/REFRACTORY DISEASE

19-021: A phase 1/2 study of oral LOXO-305 in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or non-Hodgkin Lymphoma (NHL)

**Rationale:** LOXO is a phase 1/2 study using the drug, LOXO-305, which is a small molecule that binds to the ATP site of the BTK kinase, prevents ATP from binding and inhibits BTK’s kinase activity. LOXO-305 causes potent dose-dependent inhibition of BTK kinase activity and tumor growth in multiple biologically relevant BTK-dependent model systems in vitro and in vivo, including B-cell lymphoma cell lines. The primary objective for the phase 1 study is to determine the maximum tolerated dose of oral LOXO-305 with previously treated chronic lymphocytic leukemia/ small lymphocytic lymphoma and non-Hodgkin’s lymphoma. The primary objective for the phase 2 study is to assess the preliminary anti-tumor activity of LOXO-305 based on ORR as assessed by an Independent Review committee.

**Key Eligibility Criteria:**
- Adequate hematologic status, defined as the following on C1D1 prior to treatment:
  - Absolute neutrophil count (ANC) 0.75 x 10^9/L and not requiring growth factors; if there is documented bone marrow involvement, growth factors (pegfilgastrim preferred) may be used at any time prior to C1D1 to achieve this ANC threshold
  - Platelet count 50 x 10^9/L not requiring transfusion support; if there is documented bone marrow involvement, platelet transfusion may be used prior to 7 days before C1D1 to achieve this ANC threshold
  - Hemoglobin (Hb) 8 mg/dL not requiring transfusion support or growth factors; if there is documented bone marrow involvement, growth factors (e.g., epoetin alpha) may be used at any time prior to C1D1 to achieve this Hb threshold
- At least 2 prior lines of therapy
- No more than 2 prior chemotherapy-containing treatment regimens
- Patients must have prior BTK inhibitor exposure but may have discontinued for adverse events or had disease progression.

**Treatment Schedule:**
Patients will receive the assigned LOXO-305 dose on C1D1 in clinic. Patients will continue dosing daily and will return to clinic on days 8 and 15 of cycle 1. Patients will then return to clinic on day 1 of each subsequent cycle until EOT. Patients will continue LOXO-305 dosing until PD, unacceptable toxicity other reason for treatment discontinuation. Patients with documented PD may be allowed to continue LOXO-305 if the patient is tolerating study drug and in the opinion of the Investigator, the patient is deriving clinical benefit from continuing study drug.

**Principal Investigator:** Jennifer Brown, MD, PhD

**Slots Available at Last Update:** Slots will vary but are continuously available as we can add patients to older cohorts. Please email us for the latest slot availability.

*Mantle Cell Lymphoma Clinical Trials, Dana-Farber/Brigham and Women’s Cancer Center.*
These trials are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.